These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24868521)

  • 21. Two cases of valproic acid poisoning treated with L-carnitine.
    Chan YC; Tse ML; Lau FL
    Hum Exp Toxicol; 2007 Dec; 26(12):967-9. PubMed ID: 18375641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia.
    Maldonado C; Guevara N; Queijo C; González R; Fagiolino P; Vázquez M
    Biomed Res Int; 2016; 2016():2920108. PubMed ID: 26998483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe acute hyperammonemia after brief exposure to valproate.
    Eubanks AL; Aguirre B; Bourgeois JA
    Psychosomatics; 2008; 49(1):82-3. PubMed ID: 18212182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Carnitine on Valproic Acid Pharmacokinetics in Rats.
    Katayama H; Mizukami K; Yasuda M; Hatae T
    J Pharm Sci; 2016 Oct; 105(10):3199-3204. PubMed ID: 27499337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report.
    Elgudin L; Hall Y; Schubert D
    Int J Psychiatry Med; 2003; 33(1):91-6. PubMed ID: 12906346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
    Larsen EP; Ostergaard JR
    Seizure; 2014 Jun; 23(6):429-34. PubMed ID: 24647346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valproate-associated hyperammonemic encephalopathy.
    Wadzinski J; Franks R; Roane D; Bayard M
    J Am Board Fam Med; 2007; 20(5):499-502. PubMed ID: 17823470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The decreased level of plasma carnitine in patients with epilepsy].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):106-110. PubMed ID: 28745680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-carnitine supplementation in childhood epilepsy: current perspectives.
    De Vivo DC; Bohan TP; Coulter DL; Dreifuss FE; Greenwood RS; Nordli DR; Shields WD; Stafstrom CE; Tein I
    Epilepsia; 1998 Nov; 39(11):1216-25. PubMed ID: 9821988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valproic Acid-Associated Hyperammonemia: A Systematic Review.
    Wong YJ; Fan J; Wan A; Mihic T; Gnyra M
    J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):283-294. PubMed ID: 37126830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
    Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
    Inoue K; Suzuki E; Takahashi T; Yamamoto Y; Yazawa R; Takahashi Y; Imai K; Miyakawa K; Inoue Y; Tsuji D; Hayashi H; Itoh K
    Epilepsy Res; 2014 Aug; 108(6):1046-51. PubMed ID: 24888247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X; Li X; Zhang T; Zhao L
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asymptomatic hyperammonemia in children treated with valproic acid.
    Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L
    J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804
    [No Abstract]   [Full Text] [Related]  

  • 36. Hyperammonemia due to valproic acid in the psychiatric setting.
    Carr RB; Shrewsbury K
    Am J Psychiatry; 2007 Jul; 164(7):1020-7. PubMed ID: 17606652
    [No Abstract]   [Full Text] [Related]  

  • 37. Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy.
    Ben Mahmoud L; Hakim A; Ghozzi H; Atheymen R; Sahnoun Z; Zeghal K
    Rev Neurol (Paris); 2017 Mar; 173(3):159-163. PubMed ID: 28320517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carnitine for valproic acid-induced hyperammonemia.
    Raby WN
    Am J Psychiatry; 1997 Aug; 154(8):1168-9. PubMed ID: 9247410
    [No Abstract]   [Full Text] [Related]  

  • 39. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine.
    Gidal BE; Inglese CM; Meyer JF; Pitterle ME; Antonopolous J; Rust RS
    Pediatr Neurol; 1997 May; 16(4):301-5. PubMed ID: 9258962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum carnitine, beta-hydroxybutyrate and ammonia levels during valproic acid therapy.
    Toksoy HB; Tanzer FN; Atalay A
    Turk J Pediatr; 1995; 37(1):25-9. PubMed ID: 7732605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.